Intestinal Research

Original Articles

Colorectal neoplasia

A survey of current practices in post-polypectomy surveillance in Korea: Jeongseok Kim, Tae-Geun Gweon, Min Seob Kwak, Su Young Kim, Seong Jung Kim, Hyun Gun Kim, Eun Ran Kim, Sung Noh Hong, Eun Sun Kim, Chang Mo Moon, Dae Seong Myung, Dong Hoon Baek, Shin Ju Oh, Hyun Jung Lee, Ji Young Lee, Yunho Jung, Jaeyoung Chun, Dong-Hoon Yang, on behalf of the Intestinal Tumor Research Group of the Korean Association for the Study of Intestinal Diseases (KASID); Intest Res 2024;22(2):186-207. Published online April 25, 2024; DOI: https://doi.org/10.5217/ir.2023.00109

Abstract PDF Supplementary Material PubReader ePub: Background/Aims
We investigated the clinical practice patterns of post-polypectomy colonoscopic surveillance among Korean endoscopists.
Methods
In a web-based survey conducted between September and November 2021, participants were asked about their preferred surveillance intervals and the patient age at which surveillance was discontinued. Adherence to the recent guidelines of the U.S. Multi-Society Task Force on Colorectal Cancer (USMSTF) was also analyzed.
Results
In total, 196 endoscopists completed the survey. The most preferred first surveillance intervals were: a 5-year interval after the removal of 1–2 tubular adenomas < 10 mm; a 3-year interval after the removal of 3–10 tubular adenomas < 10 mm, adenomas ≥ 10 mm, tubulovillous or villous adenomas, ≤ 20 hyperplastic polyps < 10 mm, 1–4 sessile serrated lesions (SSLs) < 10 mm, hyperplastic polyps or SSLs ≥ 10 mm, and traditional serrated adenomas; and a 1-year interval after the removal of adenomas with highgrade dysplasia, >10 adenomas, 5–10 SSLs, and SSLs with dysplasia. In piecemeal resections of large polyps ( > 20 mm), surveillance colonoscopy was mostly preferred after 1 year for adenomas and 6 months for SSLs. The mean USMSTF guideline adherence rate was 30.7%. The largest proportion of respondents (40.8%–55.1%) discontinued the surveillance at the patient age of 80–84 years.
Conclusions
A significant discrepancy was observed between the preferred post-polypectomy surveillance intervals and recent international guidelines. Individualized measures are required to increase adherence to the guidelines.

1,637 View
71 Download

IBD

Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children’s immunity: Ko Eun Lee, Sung-Ae Jung, Sang Hyoung Park, Chang Mo Moon, So Yeon Shim, Eun Soo Kim, Su Jin Cho, Seong-Eun Kim, Kwang Bum Cho, Suk-Kyun Yang; Intest Res 2019;17(2):237-243. Published online February 8, 2019; DOI: https://doi.org/10.5217/ir.2018.00071

Abstract PDF PubReader ePub

Background/Aims
The onset of inflammatory bowel disease (IBD) usually occurs at young age, and therefore, women IBD patients experience pregnancy during their disease progression. Recently, the use of anti-tumor necrosis factor-α (anti-TNF-α) has been rapidly increasing. The aim of this study was to evaluate pregnancy related outcomes in women with IBD who were treated with anti-TNF-α during pregnancy and immunity of their children.
Methods
Korean women with IBD who had been treated with anti-TNF-α during pregnancy had been enrolled. Medical records were reviewed and a survey was performed for each patient. For the patients who agreed on additional examination for their children, children’s growth, medical history and antibody to hepatitis B surface antigen (anti-HBs) titer were checked.
Results
All 18 patients had been diagnosed with Crohn’s disease. There was not any case of preterm delivery, low birth-weight infant, congenital anomaly, nor stillbirth. All 12 children had followed the regular vaccination schedule for hepatitis B and 4 of them showed negative results for anti-HBs. After the 1 booster vaccination, all children demonstrated seroconversion. Regarding live vaccines, 4 children had bacillus Calmette-Guerin and 4 had rotavirus vaccine before 6 months, without any specific side effects.
Conclusions
This was the first study of immunity of the children born from IBD women who had been treated with anti-TNF-α medication during their pregnancy. IBD women had comparable pregnancy outcomes with the general women population, suggesting that the disease activity rather than the administered medication would be more important in healthy pregnancy. Considering the history of vaccination and anti-HBs titers, immunity seems to be intact in the children.

Citations

Citations to this article as recorded by

Safety of Rotavirus Vaccination in Infants That Were Exposed to Biologics In Utero: A Systematic Review
Trevor L Schell, Lucas Fass, Mary E Hitchcock, Francis A Farraye, Mary S Hayney, Sumona Saha, Freddy Caldera
Inflammatory Bowel Diseases.2024;[Epub] CrossRef
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases
Anne R. Bass, Eliza Chakravarty, Elie A. Akl, Clifton O. Bingham, Leonard Calabrese, Laura C. Cappelli, Sindhu R. Johnson, Lisa F. Imundo, Kevin L. Winthrop, Reuben J. Arasaratnam, Lindsey R. Baden, Roberta Berard, S. Louis Bridges, Jonathan T. L. Cheah,
Arthritis & Rheumatology.2023; 75(3): 333. CrossRef
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases
Anne R. Bass, Eliza Chakravarty, Elie A. Akl, Clifton O. Bingham, Leonard Calabrese, Laura C. Cappelli, Sindhu R. Johnson, Lisa F. Imundo, Kevin L. Winthrop, Reuben J. Arasaratnam, Lindsey R. Baden, Roberta Berard, S. Louis Bridges, Jonathan T. L. Cheah,
Arthritis Care & Research.2023; 75(3): 449. CrossRef
Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy
Robert Silver, Sabrina Craigo, Flint Porter, Sarah S. Osmundson, Jeffrey A. Kuller, Mary E. Norton
American Journal of Obstetrics and Gynecology.2023; 228(3): B41. CrossRef
Vaccines in Children Exposed to Biological AgentsIn Uteroand/or During Breastfeeding: Are They Effective and Safe?
Javier P Gisbert, María Chaparro
Journal of Crohn's and Colitis.2023; 17(6): 995. CrossRef
Vaccination for rheumatic diseases: Current issues (based on ACR guidelines)
B. S. Belov, N. V. Muravyeva, E. L. Nasonov
Rheumatology Science and Practice.2023; 61(2): 151. CrossRef
Pregnancy Outcomes Associated With Biologic Agent Exposure in Patients With Several Rheumatic Diseases and Inflammatory Bowel Diseases
Soo Min Ahn, Young Bin Joo, Yun Jin Kim, So-Young Bang, Hye-Soon Lee
Journal of Korean Medical Science.2023;[Epub] CrossRef
Modern Ideas about Vaccination of Patients with Rheumatic Diseases: the View of ACR Experts
B. S. Belov, N. V. Muravyeva
Antibiotics and Chemotherapy.2023; 68(5-6): 77. CrossRef
Suboptimal Vaccination Administration in Mothers With Inflammatory Bowel Disease and Their Biologic-Exposed Infants
Helene Chiarella-Redfern, Sangmin Lee, Bellal Jubran, Nastaran Sharifi, Remo Panaccione, Cora Constantinescu, Eric I Benchimol, Cynthia H Seow
Inflammatory Bowel Diseases.2022; 28(1): 79. CrossRef
A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero
Bethan Goulden, Nicole Chua, Elaine Parker, Ian Giles
Rheumatology.2022; 61(10): 3902. CrossRef
The Risk of Adverse Neonatal Outcomes With Maternal Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Kristel K Leung, Parul Tandon, Vivek Govardhanam, Cynthia Maxwell, Vivian Huang
Inflammatory Bowel Diseases.2021; 27(4): 550. CrossRef
The Influence of Disease Activity on Pregnancy Outcomes in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Min-A Kim, Young-Han Kim, Jaeyoung Chun, Hye Sun Lee, Soo Jung Park, Jae Hee Cheon, Tae Il Kim, Won Ho Kim, Jae Jun Park
Journal of Crohn's and Colitis.2021; 15(5): 719. CrossRef
Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road
Asmaa Beltagy, Azin Aghamajidi, Laura Trespidi, Wally Ossola, Pier Luigi Meroni
Frontiers in Pharmacology.2021;[Epub] CrossRef
ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
T Kucharzik, P Ellul, T Greuter, J F Rahier, B Verstockt, C Abreu, A Albuquerque, M Allocca, M Esteve, F A Farraye, H Gordon, K Karmiris, U Kopylov, J Kirchgesner, E MacMahon, F Magro, C Maaser, L de Ridder, C Taxonera, M Toruner, L Tremblay, M Scharl, N
Journal of Crohn's and Colitis.2021; 15(6): 879. CrossRef
Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines
Eric I. Benchimol, Frances Tse, Matthew W. Carroll, Jennifer C. deBruyn, Shelly A. McNeil, Anne Pham-Huy, Cynthia H. Seow, Lisa L. Barrett, Talat Bessissow, Nicholas Carman, Gil Y. Melmed, Otto G. Vanderkooi, John K. Marshall, Jennifer L. Jones
Gastroenterology.2021; 161(2): 669. CrossRef
Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines
Eric I Benchimol, Frances Tse, Matthew W Carroll, Jennifer C deBruyn, Shelly A McNeil, Anne Pham-Huy, Cynthia H Seow, Lisa L Barrett, Talat Bessissow, Nicholas Carman, Gil Y Melmed, Otto G Vanderkooi, John K Marshall, Jennifer L Jones
Journal of the Canadian Association of Gastroenterology.2021; 4(4): e59. CrossRef
Systematic review with meta‐analysis: risk of adverse pregnancy‐related outcomes in inflammatory bowel disease
Parul Tandon, Vivek Govardhanam, Kristel Leung, Cynthia Maxwell, Vivian Huang
Alimentary Pharmacology & Therapeutics.2020; 51(3): 320. CrossRef
Safety and Optimal Timing of BCG Vaccination in Infants Born to Mothers Receiving Anti-TNF Therapy for Inflammatory Bowel Disease
Sang Hyoung Park, Hyo Jong Kim, Chang Kyun Lee, Eun Mi Song, Sang-Bum Kang, Byung Ik Jang, Eun Soo Kim, Kyeong Ok Kim, Yoo Jin Lee, Eun Young Kim, Yun Jin Jung, Soo-Kyung Park, Dong Il Park, Byong Duk Ye, Sung-Ae Jung, Suk-Kyun Yang
Journal of Crohn's and Colitis.2020; 14(12): 1780. CrossRef
Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review
N. Ghalandari, R. J. E. M. Dolhain, J. M. W. Hazes, E. P. van Puijenbroek, M. Kapur, H. J. M. J. Crijns
Drugs.2020; 80(16): 1699. CrossRef

8,163 View
221 Download
17 Web of Science
19 Crossref

IBD

Response to hepatitis B vaccination in patients with inflammatory bowel disease: a prospective observational study in Korea: Ji Young Chang, Sung-Ae Jung, Chang Mo Moon, Seong-Eun Kim, Hye-Kyung Jung, Ki-Nam Shim; Intest Res 2018;16(4):599-608. Published online October 10, 2018; DOI: https://doi.org/10.5217/ir.2018.00012

Abstract PDF PubReader ePub

Background/Aims
Testing for hepatitis B virus (HBV) serologic markers and appropriate vaccination are required in the management of inflammatory bowel disease (IBD) patients. We evaluated immunogenicity for HBV in IBD patients and the response to the HBV vaccination.
Methods
From May 2014 to August 2016, patients diagnosed with IBD were prospectively included and evaluated for anti-HBs antibody, anti-HBc antibody, and HBs antigen. Among the 73 patients who were confirmed with nonimmunity to HBV, 44 patients who had completed the 3-dose HBV vaccination series received a single booster vaccination, while 29 patients who had not completed the vaccinations series or were unsure of receiving the vaccination received a full vaccination series.
Results
An optimal response was obtained in 70.5% of the patients in the booster group, and 89.7% of the patients in the full vaccination group. Age younger than 26 years (odds ratio [OR], 6.01; 95% confidence interval [CI], 1.15–31.32; P=0.033) and a complete previous vaccination series (OR, 0.15; 95% CI, 0.03–0.80; P=0.026) were associated with optimal vaccine response. Previous complete vaccination series (OR, 0.11; 95% CI, 0.02–0.73; P=0.022) was the only predictive factor for lower compliance.
Conclusions
The response to the HBV vaccination was lower in patients older than 26 years and for those patients with a complete vaccination history. Since patients with a complete vaccination history also had poor compliance, serum HBV-titers should be checked more thoroughly, and a full vaccination series should be administered in cases when there is a negative response to the booster vaccination.

Citations

Citations to this article as recorded by

Immunogenicity of Hepatitis B Vaccination in Patients with Ulcerative Colitis on Infliximab Is Attenuated Compared to Those on 5-Aminosalicylic Acid Therapies: A Prospective Observational Study
Mohammad Shehab, Fatema Alrashed, Munerah Alyaseen, Zainab Safar, Tunrayo Adekunle, Ahmad Alfadhli, Talat Bessissow
Vaccines.2024; 12(4): 364. CrossRef
Meta‐analysis: hepatitis B vaccination in inflammatory bowel disease
Anupam Kumar Singh, Anuraag Jena, Gaurav Mahajan, Ritin Mohindra, Vikas Suri, Vishal Sharma
Alimentary Pharmacology & Therapeutics.2022; 55(8): 908. CrossRef
Efficacy of hepatitis B vaccination in patients with ulcerative colitis: a prospective cohort study
Anurag Mishra, Amarender Singh Puri, Sanjeev Sachdeva, Ashok Dalal
Intestinal Research.2022; 20(4): 445. CrossRef
A Review of Vaccinations in Adult Patients with Secondary Immunodeficiency
Elda Righi, Tolinda Gallo, Anna Maria Azzini, Fulvia Mazzaferri, Maddalena Cordioli, Mara Merighi, Evelina Tacconelli
Infectious Diseases and Therapy.2021; 10(2): 637. CrossRef
Vaccination in the Elderly and IBD
Anthony J. Choi, Preston Atteberry, Dana J. Lukin
Current Treatment Options in Gastroenterology.2019; 17(4): 492. CrossRef

7,666 View
140 Download
4 Web of Science
5 Crossref

Impact of inflammatory bowel disease on daily life: an online survey by the Korean Association for the Study of Intestinal Diseases: Young Sun Kim, Sung-Ae Jung, Kang-Moon Lee, Soo Jung Park, Tae Oh Kim, Chang Hwan Choi, Hyun Gun Kim, Won Moon, Chang Mo Moon, Hye Kyoung Song, Soo-Young Na, Suk-Kyun Yang; Intest Res 2017;15(3):338-344. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.338

Abstract PDF Supplementary Material PubReader ePub

Background/Aims

Inflammatory bowel disease (IBD) is a chronic disabling gastrointestinal disorder that diminishes the quality of life of the affected individuals. Limited data are available regarding the impact of IBD on the daily life of Koreans.

Methods

Self-administered, computer-aided, internet-based questionnaires were distributed to members of a Korean patient organization for IBD from March to April 2013, by the Korean Association for the Study of Intestinal Diseases.

Results

A total of 599 patients with IBD (387 with Crohn's disease [CD] and 212 with ulcerative colitis [UC]) were enrolled. The majority of patients (81%) expressed feelings of fatigue, weakness, and being worn out in their daily lives during times of flare; this percentage was reduced to 61% during remission. Respondents were absent from work or school for an average period of 18 days because of illness, within the first 6 months; the majority of respondents (64%) felt stressed about their absence. Forty-six percent of the respondents reported having received unfair comments at work, or having suffered discrimination. Forty-seven percent of the respondents felt that IBD had negatively affected their income and earnings. Compared with patients with UC, those with CD reported a more frequent negative impact of IBD on work, or more economic burden. More than half of the respondents (61%) reported that IBD had prevented them from making or keeping friends.

Conclusions

IBD significantly impacts daily life, including work, education, and social relationships. Treatment that addresses the full spectrum of life of a patient would be more effective.

Citations

Citations to this article as recorded by

Increased Risks for Suicide, Self-Harm, Substance Use, and Psychiatric Disorders in Adults With Inflammatory Bowel Disease: A Nationwide Study in the United States From 2007 to 2017
Chung Sang Tse, Chien-Hsiang Weng, Michelle Kwon, Courtney Benjamin Wolk, Lily A Brown, Kanika Malani, Samir A Shah, Sean D Fine
Inflammatory Bowel Diseases.2024; 30(1): 150. CrossRef
Histologic features and predicting prognosis in ulcerative colitis patients with mild endoscopic activity
Seung Yong Shin, Hee Sung Kim, Kisung Kim, Chang Won Choi, Jung Min Moon, Jeong Wook Kim, Hyun Jin Joo, Jeongkuk Seo, Muhyeon Sung, Chang Hwan Choi
The Korean Journal of Internal Medicine.2024; 39(1): 68. CrossRef
Patient experiences in ulcerative colitis: conceptual model and review of patient-reported outcome measures
Chong Kim, Fiona L. Brown, Caroline Burk, Milena Anatchkova, Nashmel Sargalo, Ankita Kaushik
Quality of Life Research.2024; 33(5): 1373. CrossRef
Colonic Dysregulation of Major Metabolic Pathways in Experimental Ulcerative Colitis
Ji Yeon Noh, Naser Farhataziz, Michael T. Kinter, Xin Yan, Yuxiang Sun
Metabolites.2024; 14(4): 194. CrossRef
A Phenomenological Investigation of Trauma in 18 Adults Living With Inflammatory Bowel Disease
Heidi Glynn, Simon R. Knowles
Clinical Nursing Research.2023; 32(1): 159. CrossRef
Interplay of broccoli/broccoli sprout bioactives with gut microbiota in reducing inflammation in inflammatory bowel diseases
Johanna Holman, Molly Hurd, Peter L. Moses, Gary M. Mawe, Tao Zhang, Suzanne L. Ishaq, Yanyan Li
The Journal of Nutritional Biochemistry.2023; 113: 109238. CrossRef
Medical consultation in ulcerative colitis: Key elements for improvement
Yago González-Lama, Elena Ricart, Ana Cábez, Pilar Fortes, Susana Gómez, Francesc Casellas
World Journal of Gastroenterology.2023; 29(6): 917. CrossRef
The relationship of major depressive disorder with Crohn's disease activity
Carolina Bortolozzo Graciolli Facanali, Carlos Walter Sobrado Junior, Renério Fraguas Junior, Marcio Roberto Facanali Junior, Lucas Rodrigues Boarini, Lucas Faraco Sobrado, Ivan Cecconello
Clinics.2023; 78: 100188. CrossRef
Characteristics and Treatment Outcomes of Transition among Patients with Inflammatory Bowel Disease
Eun Jin Yoo, Sang-Hoon Cho, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
Yonsei Medical Journal.2023; 64(9): 541. CrossRef
The impact of gastrointestinal conditions on psychosocial factors associated with the biopsychosocial model of health: A scoping review
Elizabeth Dent, Nicola Davinson, Stephanie Wilkie
Applied Psychology: Health and Well-Being.2022; 14(2): 626. CrossRef
Ilex rotunda Thunb Protects Against Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice by Restoring the Intestinal Mucosal Barrier and Modulating the Oncostatin M/Oncostatin M Receptor Pathway
Yao Li, Xu Yang, Jia-ni Yuan, Rui Lin, Yun-yuan Tian, Yu-xin Li, Yan Zhang, Xu-fang Wang, Yan-hua Xie, Si-wang Wang, Xiao-hui Zheng
Frontiers in Pharmacology.2022;[Epub] CrossRef
The association between inflammatory bowel disease and mental ill health: a retrospective cohort study using data from UK primary care
Nosheen Umar, Dominic King, Joht Singh Chandan, Neeraj Bhala, Krish Nirantharakumar, Nicola Adderley, Dawit T. Zemedikun, Phil Harvey, Nigel Trudgill
Alimentary Pharmacology & Therapeutics.2022; 56(5): 814. CrossRef
Association of inflammatory bowel disease with suicidal ideation, suicide attempts, and suicide: A systematic review and meta-analysis
Qin Xiong, Fuyou Tang, Yilin Li, Fengjiao Xie, Lei Yuan, Chengjiao Yao, Ruike Wu, Juan Wang, Qiuxiang Wang, Peimin Feng
Journal of Psychosomatic Research.2022; 160: 110983. CrossRef
Modelling symptoms to suicide risk in individuals with inflammatory bowel disease
Valentina Mihajlovic, Dean A Tripp, Jill A Jacobson
Journal of Health Psychology.2021; 26(12): 2143. CrossRef
Risk of Inflammatory Bowel Disease Following Appendectomy in Adulthood
Wei-Sheng Chung, Sunny Chung, Chung-Y Hsu, Cheng-Li Lin
Frontiers in Medicine.2021;[Epub] CrossRef
Gastrointestinal microbiome, what is behind faecal microbiota transplantation?
P. Thomson, P. Núñez, R. Quera, C. Bay
New Microbes and New Infections.2021; 42: 100898. CrossRef
Changes in Direct Healthcare Costs before and after the Diagnosis of Inflammatory Bowel Disease: A Nationwide Population-Based Study
Jooyoung Lee, Jong Pil Im, Kyungdo Han, Jihye Kim, Hyun Jung Lee, Jaeyoung Chun, Joo Sung Kim
Gut and Liver.2020; 14(1): 89. CrossRef
Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management
G. Pellino, D. S. Keller, G. M. Sampietro, V. Annese, M. Carvello, V. Celentano, C. Coco, F. Colombo, N. Cracco, F. Di Candido, M. Franceschi, S. Laureti, G. Mattioli, L. Pio, G. Sciaudone, G. Sica, V. Villanacci, R. Zinicola, S. Leone, S. Danese, A. Spin
Techniques in Coloproctology.2020; 24(2): 105. CrossRef
Inflammatory bowel disease fatigue: an analysis of definitions, risk factors and impact and their implications for assessment and management
Doireann Ni Dhalaigh, Anna Marie Greaney, Dawn Farrell
Gastrointestinal Nursing.2020; 18(5): 42. CrossRef
Unmet Psychosocial Needs of Patients with Newly Diagnosed Ulcerative Colitis: Results from the Nationwide Prospective Cohort Study in Korea
Jung Rock Moon, Chang Kyun Lee, Sung Noh Hong, Jong Pil Im, Byong Duk Ye, Jae Myung Cha, Sung-Ae Jung, Kang-Moon Lee, Dong Il Park, Yoon Tae Jeen, Young Sook Park, Jae Hee Cheon, Hyesung Kim, BoJeong Seo, Youngdoe Kim, Hyo Jong Kim
Gut and Liver.2020; 14(4): 459. CrossRef
Consensus document on the management preferences of patients with ulcerative colitis: points to consider and recommendations
Francesc Casellas, Daniel Guinard Vicens, Santiago García-López, Yago González-Lama, Federico Argüelles-Arias, Manuel Barreiro-de Acosta, Laura Marín Sánchez, Juan Manuel Mendive, Roberto Saldaña, Ana Cabez, Susana Gómez, Estíbaliz Loza
European Journal of Gastroenterology & Hepatology.2020; 32(12): 1514. CrossRef
Preconception Care Program for Women with Inflammatory Bowel Disease Using Intervention Mapping: A Protocol for Program Development
Young Jin Lee, Yeon Hee Kim, Hae Won Kim
International Journal of Environmental Research and Public Health.2020; 17(24): 9365. CrossRef
Herbs-partitioned moxibustion alleviates aberrant intestinal epithelial cell apoptosis by upregulating A20 expression in a mouse model of Crohn’s disease
Jing Zhou, Lu-Yi Wu, Liu Chen, Ya-Jing Guo, Yi Sun, Tao Li, Ji-Meng Zhao, Chun-Hui Bao, Huan-Gan Wu, Yin Shi
World Journal of Gastroenterology.2019; 25(17): 2071. CrossRef
EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain
María Chaparro, Manuel Barreiro-de Acosta, José Manuel Benítez, José Luis Cabriada, María José Casanova, Daniel Ceballos, María Esteve, Hipólito Fernández, Daniel Ginard, Fernando Gomollón, Rufo Lorente, Pilar Nos, Sabino Riestra, Montserrat Rivero, Pilar
Therapeutic Advances in Gastroenterology.2019;[Epub] CrossRef
Application of Herbaceous Medications for Inflammatory Bowel Disease as a Complementary and Alternative Therapy
Zili Lin, Huiyi Wu, Yiming Fu, Shixue Dai
Inflammatory Bowel Diseases.2019; 25(12): 1886. CrossRef
Analysis of the Nutrients and Food Products Intake of Polish Males with Ulcerative Colitis in Remission
Dominika Głąbska, Dominika Guzek, Gustaw Lech
Nutrients.2019; 11(10): 2333. CrossRef
Are there also negative effects of social support? A qualitative study of patients with inflammatory bowel disease
Alexander Palant, Wolfgang Himmel
BMJ Open.2019; 9(1): e022642. CrossRef
Reactive Oxygen Species Deficiency Due to Ncf1-Mutation Leads to Development of Adenocarcinoma and Metabolomic and Lipidomic Remodeling in a New Mouse Model of Dextran Sulfate Sodium-Induced Colitis
Lina Carvalho, Joana R. M. Gomes, Ludgero C. Tavares, Ana R. Xavier, Karel D. Klika, Rikard Holmdahl, Rui A. Carvalho, M. Margarida Souto-Carneiro
Frontiers in Immunology.2018;[Epub] CrossRef
Complementary and alternative medicine in patients with inflammatory bowel disease: A survey performed in a tertiary center in Chile
Antonia Fernández, Daniela Simian, Rodrigo Quera, Lilian Flores, Patricio Ibáñez, Jaime Lubascher, Carolina Figueroa, Udo Kronberg, Gonzalo Pizarro, Daniela Fluxá
Complementary Therapies in Medicine.2018; 40: 77. CrossRef
IBD2020 global forum: results of an international patient survey on quality of care
Peter Irving, Johan Burisch, Richard Driscoll, Mats Olsson, John R Fullarton, Barry S Rodgers-Gray, Simon PL Travis
Intestinal Research.2018; 16(4): 537. CrossRef
Association of Perianal Fistulas with Clinical Features and Prognosis of Crohn's Disease in Korea: Results from the CONNECT Study
Jaeyoung Chun, Jong Pil Im, Ji Won Kim, Kook Lae Lee, Chang Hwan Choi, Hyunsoo Kim, Jae Hee Cheon, Byong Duk Ye, Young-Ho Kim, You Sun Kim, Yoon Tae Jeen, Dong Soo Han, Won Ho Kim, Joo Sung Kim
Gut and Liver.2018; 12(5): 544. CrossRef

6,518 View
89 Download
31 Web of Science
31 Crossref

Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab: Nam Hee Kim, Yoon Suk Jung, Chang Mo Moon, Shin Yeong Lee, Eun Ran Kim, Young Ho Kim, Chang Kyun Lee, Suck Ho Lee, Jae Hak Kim, Kyu Chan Huh, Soon Man Yoon, Hyun Joo Song, Sun-Jin Boo, Hyun Joo Jang, You Sun Kim, Kang-Moon Lee, Jeong Eun Shin, Dong Il Park; Intest Res 2014;12(4):281-286. Published online October 27, 2014; DOI: https://doi.org/10.5217/ir.2014.12.4.281

Abstract PDF PubReader ePub

Background/Aims

Several recent studies have reported that the early use of infliximab (IFX) improves the prognosis of Crohn's disease (CD). However, no data are available from Asian populations, as the forementioned studies have all been conducted in Western countries. The aim of the current study was to evaluate the impact of early use of IFX on the prognosis of Korean patients with CD.

Methods

Patients with a diagnosis of CD established between July 1987 and January 2012 were investigated in 12 university hospitals in Korea. Because insurance coverage for IFX treatment began in August 2005, patients were assigned to either of 2 groups based on diagnosis date. The first group included patients diagnosed from July 1987 to December 2005, and the second from January 2006 to January 2012. We compared the cumulative probabilities of operation and reoperation between the two groups using the Kaplan-Meier method and a log-rank test.

Results

Of the 721 patients investigated, 443 (61.4%) comprized the second group. Although the cumulative probabilities of immunosuppressant (P<0.001) and IFX use (P<0.001) after diagnosis were significantly higher in the second group, there were no significant differences in cumulative probabilities of operation (P=0.905) or reoperation (P=0.418) between two groups.

Conclusions

The early use of IFX did not reduce CD-related surgery requirements in Korean patients with CD. These study results suggest that the early use of IFX may have little impact on the clinical outcome of CD in Korean patients in the setting of a conventional step-up algorithm.

Citations

Citations to this article as recorded by

Differences in the risk of clinical failure between thiopurine and methotrexate in bio-naïve patients with Crohn’s disease: a Korean nationwide population-based study
Yu Kyung Jun, Eunjeong Ji, Hye Ran Yang, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Hyuk Yoon
Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef
The Potential of Molecular Remission: Tissue Neutrophil Elastase Is Better Than Histological Activity for Predicting Long-Term Relapse in Patients With Ulcerative Colitis in Endoscopic Remission
Yu Kyung Jun, Hyeon Jeong Oh, Ji Ae Lee, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Hyuk Yoon
Inflammatory Bowel Diseases.2024;[Epub] CrossRef
Efficacy of COVID-19 vaccines in inflammatory bowel disease patients receiving anti-TNF therapy: A systematic review and meta-analysis
Dan Dou, Fangyi Zhang, Xin Deng, Yun Ma, Shuqing Wang, Xingyu Ji, Xihan Zhu, Dianpeng Wang, Shengsheng Zhang, Luqing Zhao
Heliyon.2023; 9(9): e19609. CrossRef
Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease
Rasmus Goll, Øystein K. Moe, Kay-Martin Johnsen, Renate Meyer, Joachim Friestad, Mona D. Gundersen, Hege Kileng, Knut Johnsen, Jon R. Florholmen
BMC Gastroenterology.2022;[Epub] CrossRef
Editorial: does anti‐TNF “treatment persistence” always equate to “effective treatment”? Only objective disease assessments can answer the question
Ashish Srinivasan, Daniel R. van Langenberg
Alimentary Pharmacology & Therapeutics.2021; 54(5): 718. CrossRef
Blocking tumor necrosis factor paved the way for targeted therapeutics in inflammatory diseases
Cong-Qiu Chu
Chinese Medical Journal.2021; 134(21): 2525. CrossRef
A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD
Kenechukwu O Chudy-Onwugaje, Kaci E Christian, Francis A Farraye, Raymond K Cross
Inflammatory Bowel Diseases.2019; 25(5): 820. CrossRef
Efficacy of Anti-TNF Therapy for the Treatment of Patients with Moderate-to-Severe Inflammatory Bowel Disease; a First Iranian Report
Samaneh Mohagheghi Darehranj, Sudabeh Alatab, Homayoon Vahedi, Anahita Sadeghi, Alireza Sima, Masoud Malekzadeh, Amir Anoshiravani, Hafez Fakheri, Nasser Ebrahimi Daryani, Abdolhamid Mousavi, Fariborz Mansour-Ghanaei, Mohammad Javad Zahedi, Reza Malekzade
Middle East Journal of Digestive Diseases.2019; 12(1): 12. CrossRef
Novel treatments for inflammatory bowel disease
Hyo Sun Lee, Soo-Kyung Park, Dong Il Park
The Korean Journal of Internal Medicine.2018; 33(1): 20. CrossRef
Association of Perianal Fistulas with Clinical Features and Prognosis of Crohn's Disease in Korea: Results from the CONNECT Study
Jaeyoung Chun, Jong Pil Im, Ji Won Kim, Kook Lae Lee, Chang Hwan Choi, Hyunsoo Kim, Jae Hee Cheon, Byong Duk Ye, Young-Ho Kim, You Sun Kim, Yoon Tae Jeen, Dong Soo Han, Won Ho Kim, Joo Sung Kim
Gut and Liver.2018; 12(5): 544. CrossRef
Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients
Jae Myung Cha, Dong Il Park, Sang Hyoung Park, Jeong Eun Shin, Wan Soo Kim, Suk-Kyun Yang
Journal of Korean Medical Science.2017; 32(1): 85. CrossRef
Fecal microbiota transplantation for refractory Crohn's disease
Seon Ho Bak, Hyun Ho Choi, Jinhee Lee, Mi Hee Kim, Youn Hee Lee, Jin Su Kim, Young-Seok Cho
Intestinal Research.2017; 15(2): 244. CrossRef
Long-Term Outcomes of Infliximab Treatment in 582 Korean Patients with Crohn’s Disease: A Hospital-Based Cohort Study
Sang Hyoung Park, Sung Wook Hwang, Min Seob Kwak, Wan Soo Kim, Jeong-Mi Lee, Ho-Su Lee, Dong-Hoon Yang, Kyung-Jo Kim, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Yong Sik Yoon, Chang Sik Yu, Jin-Ho Kim, Suk-Kyun Yang
Digestive Diseases and Sciences.2016; 61(7): 2060. CrossRef
Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
Eun Soo Kim, Kyeong Ok Kim, Byung Ik Jang, Chang Kyun Lee, Hyo Jong Kim, Kang-Moon Lee, You Sun Kim, Chang Soo Eun, Sung-Ae Jung, Suk-Kyun Yang, Jun Lee, Tae-Oh Kim, Yunho Jung, Geom Seog Seo, Soon Man Yoon
Gut and Liver.2016;[Epub] CrossRef
The Efficiency of Intravenous Iron Therapy in Korean Inflammatory Bowel Disease Patients
Kyeong Ok Kim
Gut and Liver.2016; 10(4): 487. CrossRef
Clinical features of Crohn's disease in Korean patients residing in Busan and Gyeongnam
Eun Ji Lee, Tae Oh Kim, Geun Am Song, Jong hun Lee, Hyung Wook Kim, Sam Ryong Jee, Seun Ja Park, Hyun Jin Kim, Jong Ha Park
Intestinal Research.2016; 14(1): 30. CrossRef
Advanced age impacts surgical characteristics and postoperative course in patients with Crohn's disease
Stanislaus Argeny, Anton Stift, Martina Mittlböck, Amy C. Lord, Svenja Maschke, Mathias Schneeweiß, Stefan Riss
International Journal of Surgery.2016; 33: 182. CrossRef
The clinical usefulness of a web-based messaging system between patients with Crohn disease and their physicians
Da Eun Jeong, Kyeong Ok Kim, Byung Ik Jang, Eun Young Kim, Jin Tae Jung, Seong Woo Jeon, Hyun Seok Lee, Eun Soo Kim, Kyung Sik Park, Kwang Bum Cho
Medicine.2016; 95(26): e4028. CrossRef
The clinical characteristics of patients with free perforation in Korean Crohn’s disease: results from the CONNECT study
Young Seok Doh, You Sun Kim, Song I Bae, Jong Pil Im, Jae Hee Cheon, Byong Duk Ye, Ji Won Kim, Young Sook Park, Ji Hyun Lee, Young-Ho Kim, Joo Sung Kim, Dong Soo Han, Won Ho Kim
BMC Gastroenterology.2015;[Epub] CrossRef
Management of Anemia in Patients with Inflammatory Bowel Disease
Kyeong Ok Kim
The Korean Journal of Gastroenterology.2015; 65(3): 145. CrossRef
Could Early Anti-Tumor Necrosis Factor Therapy Change the Prognosis of Crohn's Disease?
Byong Duk Ye
Intestinal Research.2014; 12(4): 263. CrossRef

5,086 View
56 Download
20 Web of Science
21 Crossref

Selected Summary

New Treatment Option for Recurrent Clostridium difficile Infection: Chang Mo Moon; Intest Res 2013;11(2):149-150. Published online April 30, 2013; DOI: https://doi.org/10.5217/ir.2013.11.2.149

PDF

2,065 View
17 Download

Case Reports

Postradiation Malignant Fibrous Histiocytoma of the Colon: A Case Report: Jin Young Yoon, Do Kyung Kim, Jae Hee Cheon, Chang Mo Moon, Jae Jun Park, Joo Won Chung, Eun Young Kim, Tae Hoon Kim, Chan Joo Lee, Eun Young Park, Sang Hoon Shin, Sung Pil Hong, Tae Il Kim, Nam Kyu Kim, Ho Guen Kim, Won Ho Kim; Intest Res 2010;8(1):75-79. Published online June 30, 2010; DOI: https://doi.org/10.5217/ir.2010.8.1.75

Abstract PDF: Post-radiation soft tissue sarcomas are recognized as rare complications of radiation therapy. The most common type of post-radiation soft tissue sarcoma is a malignant fibrous histiocytoma (MFH), which originates from mesenchymal cells with a predominance of histiocytes and fibroblasts. The two most common sites of occurrence for post-radiation soft tissue sarcomas are the chest wall and pelvic cavity. Post-radiation colorectal MFHs are extremely rare and all of the reported cases of post-radiation sarcomas have occurred ＞3 years after radiation therapy. Recently, we managed a case of colorectal MFH which developed in a 48-year-old male who had undergone a low anterior resection for rectal adenocarcinoma and had received chemoradiotherapy as adjuvant treatment. Twelve months after radiotherapy, a 4 cm mass was detected 8 cm superior to the anastomosis site on colonoscopic examination. A soft tissue sarcoma was suspected on pathologic examination of the biopsy specimen. Therefore, he underwent a Hartmann's operation and the final pathologic finding revealed MFH with a storiform pattern of tumor cells composed of pleomorphic, multinucleated giant cells. This is the first case of MFH that had a latency period ＜3 years (i.e., 1 year) between the time of radiotherapy and diagnosis. (Intest Res 2010;8:75-79)

2,415 View
14 Download

A Case of Ileal Mucormycosis in a Patient with Gastrointestinal Behcet's Disease: Song Yi Han, Duk Hwan Kim, Jae Jun Park, Chang Mo Moon, Eun Soo Kim, Jae Hee Cheon, Tae Il Kim, Seung Hyuk Baik, Hogeun Kim, Won Ho Kim; Intest Res 2008;6(2):140-144. Published online December 30, 2008

Abstract PDF: Zygomycosis (mucormycosis) is a rare fungal infectious disease, usually found in association with an immunocompromised state. Gastrointestinal mucormycosis is extremely rare and fatal, thus it is important to detect and manage this disease at an early stage in an effort to improve survival. To date, no cases of mucormycosis superimposed on gastrointestinal Behcet's disease have been reported. Herein we report a case in which gastrointestinal mucormycosis occurred in a 17-year-old-female with Behcet's disease. The patient recovered from her disease after undergoing an ileocecectomy. (Intest Res 2008;6:140-144)

1,673 View
16 Download

First
Prev
Page of 1
Next
Last

Search